INmune Bio Inc. (INMB) Discusses XPro1595 Phase II MINDFuL Results and Registrational Strategy in Alzheimer's Disease Transcript
Source: SeekingAlpha
2026-02-27 13:37:47 ET
INmune Bio Inc. (INMB) Discusses XPro1595 Phase II MINDFuL Results and Registrational Strategy in Alzheimer's Disease February 27, 2026 9:30 AM EST...
Read the full article on Seeking Alpha
For further details see:
INmune Bio Inc. (INMB) Discusses XPro1595 Phase II MINDFuL Results and Registrational Strategy in Alzheimer's Disease Transcript
INmune Bio Inc.
NASDAQ: INMB
INMB Trading
9.96% G/L:
$1.38 Last:
90,888 Volume:
$1.30 Open:
INMB Latest News
February 23, 2026 09:25:00 am
INmune Bio to Detail XPro1595 Registrational Strategy in Upcoming Alzheimer's Webinar
February 19, 2026 12:15:00 pm
INmune Bio Announces Upcoming Webinar to Present New Clinical Data on CORDStrom(TM) for RDEB
INMB Stock Data
$100,001,939
20,608,626
3.69%
19
N/A
Biotechnology & Life Sciences
Healthcare
US
Boca Raton
